Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SFDA Issues Recall System For Medical Devices

This article was originally published in PharmAsia News

Executive Summary

China's State FDA released a draft on administrative measures for medical device recalls on March 19. The report specifies the responsibility, recall scope, time limit, classification and legal liabilities of medical device recalls, mainly aimed at device manufacturers. Recall falls into two types: voluntary and compulsory. Based on the potential safety hazard of medical devices, three categories of recall have been classified: devices that must be recalled within 24 hours, 48 hours and 72 hours. Industry analysts observe that as most local medical devices makers are small-scale enterprise, they may not be able to bear losses. However, the new recall system will have a profound impact on enhancing manufacturers' quality control and focus on their medical devices. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel